EUVIMEDEUVIMED entdecken
Crossref

Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival

Amir Ashraf Ganjouei, Jane Wang, Sophia Hernandez, Laleh Foroutani, Fernanda Romero Hernandez, Kenzo Hirose, Eric Nakakura, Carlos Corvera, Adnan Alseidi, Mohamed Abdelgadir Adam

Annals of Surgical Oncology · 2026-08 · 33 (8) · 7520-7526

DOI: 10.1245/s10434-026-19829-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Surgical Oncology, online erschienen am 19.05.2026. Verfasst von Amir Ashraf Ganjouei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Neoadjuvant Therapy, Pancreatectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The survival benefit of neoadjuvant chemotherapy (NAC) in early-stage pancreatic ductal adenocarcinoma (PDAC) remains uncertain. Although retrospective studies often suggest improved outcomes, these findings may be confounded by immortal time bias (ITB), the interval between diagnosis and treatment during which patients must survive to receive therapy, potentially inflating survival estimates. This study applied multiple bias-adjusted analytic methods to re-evaluate the association between NAC and overall survival in early-stage PDAC. METHODS: Using the National Cancer Database (2012-2017), we identified adults with resectable clinical T1 and T2 PDAC who underwent pancreatectomy. Overall survival was compared between multiagent NAC and upfront surgery by using Kaplan-Meier and multivariable Cox models. We used three statistical approaches to adjust for immortal time bias: 1) a 9-month landmark analysis; 2) a time-varying Cox regression model; and 3) a propensity-matched time-varying Cox model. RESULTS: Among 13,466 patients, 15.8% received NAC. Before bias adjustment, NAC was associated with longer median survival (33.4 vs. 25.7 months; HR 0.78, p < 0.001). However, after correcting for immortal time bias, this apparent survival advantage disappeared: landmark analysis (HR 0.94, p = 0.072), time-varying model (HR 1.06, p = 0.2), and matched cohort (HR 0.94, p = 0.2). CONCLUSIONS: This study shows that ITB significantly influences survival estimates in retrospective analyses of NAC for early-stage resectable PDAC. When appropriately adjusted, NAC was not associated with a survival advantage compared to upfront surgery. These findings underscore the need for methodological rigor in retrospective studies and caution against overinterpreting unadjusted survival advantages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsNeoadjuvant TherapyPancreatectomyAntineoplastic Combined Chemotherapy ProtocolsHumansSurvival RateFemaleAgedMaleRetrospective StudiesChemotherapy, AdjuvantMiddle AgedNeoplasm StagingFollow-Up StudiesPrognosisBias

Stichwörter der Autor:innen

Immortal time biasNCDBNeoadjuvant chemotherapyPancreatic ductal adenocarcinomaSurvival analysisUpfront surgery

Autor:innen und Institutionen

  • Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
  • Department of Surgery, University of California, San Francisco, San Francisco, CA, USA. Mohamed.Adam@ucsf.edu.
  • Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, USA. Mohamed.Adam@ucsf.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ashraf Ganjouei, A., Wang, J., Hernandez, S., Foroutani, L., Hernandez, F. R., Hirose, K., Nakakura, E., Corvera, C., Alseidi, A., & Adam, M. A. (2026). Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Annals of Surgical Oncology, 33(8), 7520-7526. https://doi.org/10.1245/s10434-026-19829-1

Vancouver

Ashraf Ganjouei A, Wang J, Hernandez S, Foroutani L, Hernandez FR, Hirose K, et al. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Annals of Surgical Oncology. 2026;33(8):7520-7526. doi:10.1245/s10434-026-19829-1

BibTeX
@article{AshrafGanjouei2026,
  author = {Ashraf Ganjouei, Amir and Wang, Jane and Hernandez, Sophia and Foroutani, Laleh and Hernandez, Fernanda Romero and Hirose, Kenzo and Nakakura, Eric and Corvera, Carlos and Alseidi, Adnan and Adam, Mohamed Abdelgadir},
  title = {Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival},
  journal = {Annals of Surgical Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {7520--7526},
  doi = {10.1245/s10434-026-19829-1}
}
Kostenlos starten →